Platelet-Rich Plasma Combined with Alendronate Reduces Pain and Inflammation in Induced Osteoarthritis in Rats by Inhibiting the Nuclear Factor-Kappa B Signaling Pathway.
Alendronate
/ pharmacology
Animals
Arthralgia
/ metabolism
Bone Density Conservation Agents
/ pharmacology
Cells, Cultured
Chondrocytes
/ metabolism
Disease Models, Animal
Inflammation
/ metabolism
NF-kappa B
/ metabolism
Osteoarthritis
/ metabolism
Platelet-Rich Plasma
Rats
Rats, Sprague-Dawley
Signal Transduction
/ drug effects
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
07
2020
accepted:
24
08
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
11
5
2021
Statut:
epublish
Résumé
Osteoarthritis (OA) is one of the common degenerative diseases of the joint in the world. This study was designed to explore the effect of platelet-rich plasma (PRP) combined with alendronate (ALN) on OA. We induced OA model by anterior cruciate ligament transection (ACLT) method in rats and treating chondrocytes by IL-1 Treatment with PRP, ALN, or PRP combined with ALN decreased the degree of cartilage destruction, the mRNA expression of MMP-13 and inflammatory factors (IL-18, IL-1 PRP combined with ALN delayed OA progression by inhibiting the NF-
Identifiants
pubmed: 33062701
doi: 10.1155/2020/8070295
pmc: PMC7539111
doi:
Substances chimiques
Bone Density Conservation Agents
0
NF-kappa B
0
Alendronate
X1J18R4W8P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8070295Informations de copyright
Copyright © 2020 Feng Xin et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
PLoS One. 2017 Apr 18;12(4):e0176107
pubmed: 28419155
PLoS One. 2017 Apr 13;12(4):e0175682
pubmed: 28406954
Mol Med Rep. 2017 Aug;16(2):1837-1845
pubmed: 28627596
Am J Sports Med. 2018 Mar;46(4):977-986
pubmed: 29373806
Osteoarthritis Cartilage. 2017 Feb;25(2):297-308
pubmed: 27756697
J Orthop Res. 1992 Jan;10(1):58-61
pubmed: 1727936
Exp Ther Med. 2020 Jan;19(1):722-728
pubmed: 31885710
Am J Manag Care. 2009 Sep;15(8 Suppl):S223-9
pubmed: 19817508
Mol Med Rep. 2017 May;15(5):2940-2948
pubmed: 28339078
Int Immunopharmacol. 2020 Jan;78:106043
pubmed: 31837574
Histol Histopathol. 2016 Jun;31(6):635-45
pubmed: 26631351
Mol Med Rep. 2019 Jul;20(1):312-322
pubmed: 31115524
Am Fam Physician. 2000 Aug 1;62(3):565-70, 572
pubmed: 10950213
Int Immunopharmacol. 2020 Jan;78:105954
pubmed: 31757676
Bone. 2013 Apr;53(2):340-9
pubmed: 23291609
Biochem Biophys Res Commun. 2019 Sep 10;517(1):132-139
pubmed: 31307784
Int J Mol Med. 2016 Dec;38(6):1922-1932
pubmed: 27748894
Ann Rheum Dis. 2008 Oct;67(10):1358-9
pubmed: 18791054
Am J Sports Med. 2011 Feb;39(2):266-71
pubmed: 21051428
Osteoarthritis Cartilage. 2020 Mar;28(3):296-315
pubmed: 31887390
Ann Rheum Dis. 2017 May;76(5):914-922
pubmed: 27965260
Drug Des Devel Ther. 2019 Oct 15;13:3559-3568
pubmed: 31686786
J Orthop Res. 2011 Oct;29(10):1572-7
pubmed: 21462250
Arq Bras Endocrinol Metabol. 2014 Jul;58(5):523-9
pubmed: 25166043
Mol Neurobiol. 2017 Mar;54(2):983-996
pubmed: 26797519
Arthritis Res Ther. 2017 Jul 25;19(1):175
pubmed: 28743292
Biomaterials. 2014 Dec;35(36):9599-607
pubmed: 25176059
Am J Med Sci. 2018 Jan;355(1):6-12
pubmed: 29289264
Med Sci Monit. 2016 Apr 17;22:1280-90
pubmed: 27086145
Arthritis Res Ther. 2017 May 15;19(1):94
pubmed: 28506315
Curr Rheumatol Rep. 2017 Sep;19(9):53
pubmed: 28752488
Oxid Med Cell Longev. 2019 Dec 14;2019:9705929
pubmed: 31915516
Int Immunopharmacol. 2019 Oct;75:105715
pubmed: 31310911
Oncotarget. 2017 Jun 13;8(24):38602-38617
pubmed: 28418842
N Engl J Med. 1998 Jul 30;339(5):292-9
pubmed: 9682041
Int Immunopharmacol. 2019 Dec;77:105928
pubmed: 31711940